Using small antibodies to diagnose and treat Alzheimer's disease
Official title: Single domain antibodies for diagnosis and treatment of synucleinopathies
Funded at New York University School of Medicine · NIH-10915130 · Data updated 2026-11-12
This study is exploring new, smaller antibodies that could help find and remove harmful proteins linked to Alzheimer's disease, aiming to create better ways to diagnose and treat patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 30, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $717,491 |
| NIH project number | 1R56AG083436-01 |
| Project ID | NIH-10915130 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related synucleinopathies.
✕Less likely to help
Patients with other forms of dementia not related to amyloid-β or α-synuclein may not benefit from this research.
What this research studies
This research focuses on developing single domain antibodies that can target and potentially clear harmful proteins associated with Alzheimer's disease, such as amyloid-β and α-synuclein. By utilizing smaller antibody fragments, the study aims to improve diagnostic imaging and therapeutic efficacy compared to traditional whole antibodies. The researchers will assess the ability of these antibodies to detect and eliminate these proteins in living organisms, which could lead to innovative treatment options for patients. The project involves advanced techniques such as phage display libraries and in vivo imaging to evaluate the effectiveness of these antibody fragments.
Why it matters
Potential benefit: If successful, this research could lead to more effective diagnostic tools and treatments for Alzheimer's disease, improving patient outcomes.
How similar studies have gone: While immunotherapies targeting amyloid-β and α-synuclein are being explored, the specific use of single domain antibodies is a novel approach that has not been extensively tested.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Sigurdsson, Einar M — New York University School of Medicine
- Study coordinator: Sigurdsson, Einar M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.